Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd Mogappair

Chennai, India

Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd Mogappair

Chennai, India

Time filter

Source Type

Gururajan P.,Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd | Gurumurthy P.,Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd | Nayar P.,Chettinad Hospital and Research Institute | Srinivasa Nageswara Rao G.,Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd | And 2 more authors.
Heart Lung and Circulation | Year: 2010

Aims and objectives: Diagnosis of myocardial ischaemia at an early stage in the emergency department is often difficult. A recently proposed biomarker, heart fatty acid binding protein (H-FABP) has been found to appear in the circulation superior to that of cardiac troponins in the early hours of acute coronary syndrome. We proposed to evaluate the levels of H-FABP and ascertain its utility as an early biomarker for acute coronary syndrome (ACS). Methods and results: The present study was carried out in 485 subjects, of whom 297 were diagnosed as patients with ACS, 89 were diagnosed as non-cardiac chest pain (NCCP) and 99 people served as healthy controls. H-FABP levels were measured in comparison with standard markers such as troponin I and CK-MB in all subjects enrolled in the study. The levels of H-FABP were significantly raised in patients when compared to controls and NCCP (P<0.001). Receiver Operator Characteristic Curve (ROC) analysis showed H-FABP to be a good discriminator between patients with ischaemic heart disease and patients without ischaemic heart disease. The area under the curve was found to be 0.965 with 95% CI (0.945-0.979). The cut-off value above which H-FABP can be considered positive was found to be 17.7. ng/ml. Conclusion: H-FABP is a promising biomarker for the early detection of patients with acute coronary syndrome. © 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand.


PubMed | Chettinad Hospital and Research Institute, Dr KM Cherian Heart Foundation a unit of Frontier LifeLine Pvt Ltd ; Mogappair and Dr KM Cherian Heart Foundation a unit of Frontier LifeLine Pvt Ltd Mogappair
Type: Journal Article | Journal: Heart Asia | Year: 2016

Myeloperoxidase, an abundant leucocyte enzyme, is elevated in culprit lesions that have ruptured in patients with sudden cardiac injury. Multiple lines of evidence suggest an association between myeloperoxidase and inflammation and acute coronary syndrome. Myeloperoxidase has been proposed as a potent risk marker and diagnostic tool in acute coronary syndrome (ACS). Recent studies have reported the potential use of myeloperoxidase in acute coronary syndrome, but limited reports are available on its utility in different groups of ACS in the emergency department. Therefore the circulating levels of serum myeloperoxidase in patients with acute coronary syndrome and control subjects were studied.The levels of serum myeloperoxidase were measured by ELISA in 485 patients admitted to emergency care unit, of which 89 patients were diagnosed as non-cardiac chest pain (NCCP). The levels of myeloperoxidase were significantly increased in patients with ACS when compared with controls and NCCP. From the receiver operator characteristic (ROC) curve analysis, the optimum value above which myeloperoxidase can be considered positive was found to be 48.02 U/ml. The area under the curve was found to be 0.956 with 95% CI (0.934 to 0.973) (p<0.0001). A combination analysis of ROC curves of troponin, creatine kinase MB (CK-MB) and myeloperoxidase showed myeloperoxidase to be highly significant. Multivariate analysis revealed myeloperoxidase to be an independent diagnostic marker for early diagnosis of ACS.Myeloperoxidase, in contrast to troponin and CK-MB, identified patients at risk of ischaemic events, even in the absence of myocardial necrosis, thus highlighting its potent usefulness for risk stratification among patients presenting with chest pain.

Loading Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd Mogappair collaborators
Loading Dr K.M Cherian Heart Foundation A Unit of Frontier LifeLine Pvt Ltd Mogappair collaborators